Hypofractionated vs. Conventional Chemoradiotherapy After Induction Chemo-immunotherapy for Unresectable Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

Esophageal Squamous Cell Carcinoma (ESCC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Sun yat-sen University Cancer Center, Guangzhou, Guangdong, China
Contact: Study coordinator (Hui Liu, MD) · liuhuisysucc@126.com · 02087343031

Study leads

Hui Liu, Professor
Principal Investigator
Sun yat-sen universtiy cancer center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma

Borderline Resectable Carcinoma · Unresectable Cancer · Esophageal Squamous Cell Carcinoma (ESCC)

Abroad (travel likely)RecruitingPHASE2

Shantou, China

Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC

Esophageal Squamous Cell Carcinoma · Chemotherapy Effect · Side Effect of Drug

Abroad (travel likely)Recruiting

Nanjing, China

Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC

Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Shanghai, China

Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC

Esophageal Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Xi'an, China